Skip to main content

Table 1 Clinical characteristics

From: Myocardial perfusion is impaired in asymptomatic renal and liver transplant recipients: a cardiovascular magnetic resonance study

  Renal transplant subjects (n = 20) Liver transplant subjects (n = 15) Hypertensive controls (n = 10) p-value*
Age, years (mean ± SD) 55 ± 11 61 ± 6 55 ± 11 0.17
Male sex, n (%) 11 (55) 12 (80) 5 (50) 0.18
BMIa, kg/m2 (mean ± SD) 29 ± 5 30 ± 4 33 ± 3 0.26
eGFRb, mL/min/1.73 m2 (mean ± SD) 78 ± 19 89 ± 29 108 ± 30 0.009
Systolic Blood Pressure (mmHg) 131 ± 19 130 ± 14 140 ± 11 0.26
Diastolic Blood Pressure (mmHg) 77 ± 14 80 ± 9 80 ± 11 0.74
Heart Rate (beats per minute) 71 ± 11 64 ± 9 77 ± 15 0.02
Cardiovascular Risk Factors, n (%)
   Hypertension 18 (90) 9 (60) 10 (100) 0.03
   Diabetes Mellitus 3 (15) 4 (27) 2 (20) 0.62
   Total cholesterol (mmol/L) 4.8 ± 1.2 4.5 ± 1.1 5.7 ± 1.0 0.06
   Low-density lipoprotein (mmol/L) 2.1 ± 1.1 2.6 ± 1.0 3.6 ± 0.9 0.005
  Triglyceride (mmol/L) 2.3 ± 1.4 1.5 ± 0.6 1.5 ± 0.7 0.08
  Smoking History 7 (35) 6 (40) 3 (30) 1.00
Cardiac Medications, n (%)
   Aspirin 1 (5) 0 (0) 2 (20) 0.14
   Beta blocker 9 (45) 3 (20) 2 (20) 0.29
   ACEc inhibitor 5 (25) 1 (7) 2 (20) 0.41
   Angiotensin Receptor Blocker 3 (15) 1 (7) 5 (50) 0.07
   Calcium channel blocker 5 (25) 5 (33) 5 (50) 0.54
   Statin 7 (35) 0 (0) 2 (20) 0.03
  1. Data are presented as n (%) or mean ± SD
  2. *Assessed using ANOVA or Fisher’s exact as appropriate
  3. aBMI indicates body mass index
  4. beGFR, estimated Glomerular Filtration Rate
  5. cACE, angiotensin-converting enzyme